Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology · Vasoactive Intestinal Peptide-Producing Tumor

Understanding VIPoma and Urgent Warning Signs

At a Glance

VIPoma can trigger a hormonal crisis before the tumor causes other problems: excess VIP causes persistent watery diarrhea, severe fluid and potassium loss, dehydration, and dangerous heart or kidney complications. Emergency hospital care focuses on IV fluids, electrolytes, monitoring, and octreotide.

A diagnosis of VIPoma means you are dealing with an incredibly rare condition. It is estimated to affect only about 1 in every 10 million people each year [1]. Because it is so rare, most doctors will never see a single case in their entire career. For this reason, it is essential that your care is managed by a dedicated neuroendocrine tumor (NET) specialist team [2].

A VIPoma is a type of tumor, usually found in the pancreas, that overproduces a hormone called Vasoactive Intestinal Peptide (VIP) [3]. In a healthy body, VIP helps regulate digestion, but when your body is flooded with too much of it, it forces your intestines to secrete massive amounts of water and salts. This leads to a cluster of symptoms known as WDHA syndrome (Watery Diarrhea, Hypokalemia, and Achlorhydria) [4].

The Immediate Priority: Hormonal Crisis vs. Tumor Growth

While VIPomas are oncological (cancer) growths that require staging and treatment, the hormone they release can be an immediate, life-threatening danger [2]. Other functional neuroendocrine tumors can also cause acute crises, but VIPoma is known for its profound fluid effects.

The primary threat at the time of diagnosis is often not the tumor’s size or spread, but the “hormonal crisis” it creates [5]. The sheer volume of fluid and minerals lost through diarrhea can lead to organ injury before the tumor itself causes physical blockages [6]. Your medical team must prioritize stabilizing your fluids and electrolytes, which can proceed in parallel with evaluating the tumor [5][2].

Red Flags: When to Seek Emergency Care

VIPoma-associated diarrhea is “secretory,” meaning it does not typically stop when you fast or stop eating [7]. It can reach volumes of over 3 liters (nearly a gallon) per day [7]. This massive loss of fluid and salt can lead to hypovolemia (dangerously low blood volume) and shock [5][8].

Safety Warning: Do not attempt to self-treat severe diarrhea or potassium loss with over-the-counter supplements, bicarbonate, or antidiarrheals. Go to the emergency room immediately if you experience any of the following:

  • Signs of Massive Dehydration: Severe dizziness, fainting (syncope), or feeling like you will faint when standing; a rapid or “racing” heartbeat; and a significant decrease in urination (which may signal acute kidney injury) [9][6].
  • Severe Potassium Loss (Hypokalemia): Profound muscle weakness, such as being unable to walk or lift your arms; painful muscle cramps; or a feeling of “fluttering” in your chest (palpitations), which can indicate dangerous heart rhythm changes [10][2].
  • Neurological Changes: New confusion, extreme lethargy, or feeling “foggy,” which can result from severe electrolyte imbalances or acidosis (excess acid in the blood) [11][12].

Understanding WDHA Syndrome

The three main components of this syndrome work together to disrupt your body’s balance:

  1. Watery Diarrhea: This is the hallmark of the condition. It is profuse, high-volume, and persistent [7].
  2. Hypokalemia: This refers to low levels of potassium, a vital mineral for heart and muscle function [3]. Because the intestines are forced to dump potassium along with water, levels can drop to dangerous lows (for example, below 2.5 mmol/L is considered severe), putting you at risk for cardiac issues [10][2].
  3. Achlorhydria: This is the absence of hydrochloric acid in the stomach [4]. While this contributes to the syndrome, it is the least dangerous of the three components in an emergency setting.

Acute Management in the Hospital

If you are admitted to the hospital, the focus will be on resuscitation [13]. This typically involves:

  • Intensive IV Fluids: Large volumes of intravenous fluids to replace what is being lost, directed by measured stool output and kidney function [5].
  • Electrolyte Replacement: Doses of potassium and magnesium, often delivered through an IV under ECG monitoring, to protect your heart [5][13].
  • Somatostatin Analogues: Drugs like octreotide are often started promptly. These medications can help reduce the tumor’s hormone production, significantly reducing the diarrhea and allowing your body to stabilize [14][5].

Once you are stabilized and the fluid loss is under control, your specialist team will then begin the process of staging the tumor and discussing long-term treatment options, such as surgery or targeted therapies [2][15].

Common questions in this guide

What is VIPoma and what is WDHA syndrome?
VIPoma is a rare neuroendocrine tumor, usually in the pancreas, that produces too much vasoactive intestinal peptide. The excess hormone causes persistent watery diarrhea and loss of potassium and other fluids; the combination of watery diarrhea, low potassium, and achlorhydria is called WDHA syndrome.
When should I go to the emergency room for VIPoma symptoms?
Seek emergency care for severe or ongoing watery diarrhea with fainting, severe dizziness, a racing heartbeat, markedly reduced urination, profound weakness, palpitations, confusion, or extreme sleepiness. These signs can indicate dangerous dehydration, low potassium, kidney injury, shock, or other electrolyte problems.
How is a VIPoma-related hormonal crisis treated in the hospital?
Hospital teams replace lost fluid through IV fluids and correct potassium and magnesium, often with heart-rhythm monitoring. Octreotide or another somatostatin analogue may be started to reduce VIP release and diarrhea. After stabilization, specialists stage the tumor and discuss surgery or targeted therapies.
Why is octreotide used for VIPoma?
Octreotide is a somatostatin analogue that can suppress hormone production by a VIPoma. By lowering VIP release, it may reduce high-volume diarrhea and help control fluid and electrolyte loss while other evaluation and treatment proceed.
Why should VIPoma care involve a specialist team?
VIPoma is extremely rare and can cause a dangerous hormonal crisis even while the tumor is being evaluated. A team experienced with neuroendocrine tumors can coordinate fluid and electrolyte stabilization, heart and kidney monitoring, tumor staging, and longer-term treatment.

Get notified when new evidence is published on pancreatic vasoactive intestinal peptide producing tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Vasoactive intestinal peptide secreting tumour: An overview.

    Una Cidon E

    World journal of gastrointestinal oncology 2022; (14(4)):808-819 doi:10.4251/wjgo.v14.i4.808.

    PMID: 35582098
  2. 2

    Treatment options of metastatic and nonmetastatic VIPoma: a review.

    Azizian A, König A, Ghadimi M

    Langenbeck's archives of surgery 2022; (407(7)):2629-2636 doi:10.1007/s00423-022-02620-7.

    PMID: 35931878
  3. 3

    All you need to know about VIPoma: Review on the latest studies.

    Karele EN

    Presse medicale (Paris, France : 1983) 2024; (53(2)):104222 doi:10.1016/j.lpm.2023.104222.

    PMID: 38109967
  4. 4

    Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system.

    Iwasaki M, Akiba Y, Kaunitz JD

    F1000Research 2019; (8()) doi:10.12688/f1000research.18039.1.

    PMID: 31559013
  5. 5

    Metastatic mixed VIPoma/PPoma-induced diarrhoea causing renal failure.

    Brown G, Monaghan AM, Fristedt R, et al.

    Endocrinology, diabetes & metabolism case reports 2022; (2022()).

    PMID: 36001009
  6. 6

    Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma.

    Negro A, Verzicco I, Tedeschi S, et al.

    Frontiers in endocrinology 2021; (12()):652045 doi:10.3389/fendo.2021.652045.

    PMID: 33815297
  7. 7

    Pancreatic VIPomas from China: Case reports and literature review.

    Chen C, Zheng Z, Li B, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2019; (19(1)):44-49 doi:10.1016/j.pan.2018.10.007.

    PMID: 30391116
  8. 8

    Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature.

    Hu X, Cao W, Zhao M

    World journal of clinical cases 2018; (6(14)):862-868 doi:10.12998/wjcc.v6.i14.862.

    PMID: 30510956
  9. 9

    Percutaneous Cryoablation of Recurrent Pancreatic Mass for Life-Threatening Pancreatic VIPoma Syndrome: A Case Report.

    Eng K, Wiseman D, Van Uum S, et al.

    Cardiovascular and interventional radiology 2021; (44(1)):163-166 doi:10.1007/s00270-020-02630-2.

    PMID: 32914368
  10. 10

    Successful Treatment of Hypokalemic Rhabdomyolysis Caused by a Pancreatic VIPoma: A Case Report.

    Ramirez S, Lytle M, Togores E, et al.

    The American journal of case reports 2019; (20()):1723-1727 doi:10.12659/AJCR.918213.

    PMID: 31754090
  11. 11

    Pancreatic Vasoactive Intestinal Peptide-Producing Tumor as a Rare Cause of Acute Diarrhea and Severe Hypokalemia.

    Giampatzis V, Kotsiari C, Bostantzis P, et al.

    Journal of medical cases 2023; (14(9-10)):307-316 doi:10.14740/jmc4141.

    PMID: 37868325
  12. 12

    Chronic Diarrhea Caused by Vasoactive Intestinal Peptide-Secreting Tumor.

    Belei O, Basaca DG, Heredea ER, et al.

    Life (Basel, Switzerland) 2023; (13(10)) doi:10.3390/life13101974.

    PMID: 37895355
  13. 13

    Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome.

    Boesenkoetter J, Ellrichmann I, Konukiewitz B, et al.

    JCEM case reports 2024; (2(10)):luae177 doi:10.1210/jcemcr/luae177.

    PMID: 39351119
  14. 14

    Efficacy of treatments for VIPoma: A GTE multicentric series.

    Brugel M, Walter T, Goichot B, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(8)):1531-1539 doi:10.1016/j.pan.2021.08.001.

    PMID: 34404601
  15. 15

    Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

    Bartsch DK, Mais L, de Mestier L, et al.

    Journal of neuroendocrinology 2026; (38(7)):e70219 doi:10.1111/jne.70219.

    PMID: 42338092

This page explains VIPoma warning signs and emergency treatment for educational purposes only; it does not constitute medical advice. Seek emergency care for severe diarrhea, dehydration, weakness, palpitations, confusion, or reduced urination, and ask your clinical team about your specific situation.